NOVO NORDISK’s stocks fell on Monday after the company Reported Since the next -generation obesity drugs have produced weight loss, diabetes patients did not meet the expectations of investors, and the second main data was disappointed by financial observers.
In the late exams of people with obesity and type 2 diabetes, treatment called Cagrisema reduced the patient by 13.7% of weight for 68 weeks, including all participants, including patients. Considering only the participants who were treated, they lost 15.7%of weight loss.
In particular, CAGRIEMA’s early mid -stage test found that obesity and diabetic patients lost 15.6%of their weight for 32 weeks. However, in the new reviews, NOVO integrated the flexible medication protocol so that the patient could modify the dosage rather than maintaining the highest dose. At the end of the study, 62%of patients have the highest dosage, Novo said.
This article applies only to STAT+ subscribers.
Join STAT+to unlock the daily coverage and analysis of this article and pharmaceutical industry.
Is there an account already? Log in
Look at all plans
